A nanoparticle formulation that selectively transfects metastatic tumors in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 36, 2013, Pages 14717-14722

  Yang, Jian ^a,b,c   Hendricks, William ^a,b,c   Liu, Guosheng ^c,d   McCaffery, J Michael ^e   Kinzler, Kenneth W ^a,b,c   Huso, David L ^c,d   Vogelstein, Bert ^a,b,c   Zhou, Shibin ^a,b,c  

^a Ludwig Center for Cancer Genetics and Therapeutics   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MACROGOL; NANOPARTICLE; POLYETHYLENEIMINE; MACROGOL DERIVATIVE; PHOTOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER LOCALIZATION; COLORECTAL CANCER; CONTROLLED STUDY; GENETIC TRANSFECTION; IN VIVO GENE TRANSFER; METASTASIS; MOLECULAR WEIGHT; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STROMA CELL; TRANSGENE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG SCREENING; GENE THERAPY; GENETICS; HCT116 CELL LINE; HEPG2 CELL LINE; HT 29 CELL LINE; HUMAN; KNOCKOUT MOUSE; METABOLISM; NEOPLASMS; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALIA; MUS;

ANIMALS; CELL LINE; CELL LINE, TUMOR; GENETIC THERAPY; HCT116 CELLS; HEP G2 CELLS; HT29 CELLS; HUMANS; LUMINESCENT PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, NUDE; MICE, SCID; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NEOPLASM METASTASIS; NEOPLASMS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883355024     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1313330110     Document Type: Article

References (41)

1. Vogelstein B, et al. (2013) Cancer genome landscapes. Science 339(6127):1546-1558.
2. Papadopoulos N, Kinzler KW, Vogelstein B (2006) The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotechnol 24(8):985-995. (Pubitemid 44215393)
3. Irshad S, Ashworth A, Tutt A (2011) Therapeutic potential of PARP inhibitors for metastatic breast cancer. Expert Rev Anticancer Ther 11(8):1243-1251.
4. Chapman PB, et al.; BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516.
5. Sequist LV, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26.
6. Wilson TR, et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487(7408):505-509. 10.1038/nature11249.
7. Diaz LA, Jr., et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404):537-540.
8. Jain RK, Duda DG (2008) Vascular and interstitial biology of tumors. Abeloff's Clinical Oncology, eds Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (Churchill Livingstone Elsevier, Philadelphia), 4th Ed, Vol 1, pp 105-124.
9. Yuan F, et al. (1995) Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55(17):3752-3756.
10. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK (2000) Vascular permeability in a human tumour xenograft: Molecular charge dependence. Br J Cancer 82(9):1513-1518. (Pubitemid 30204355)
11. Maeda H, Fang J, Inutsuka T, Kitamoto Y (2003) Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications. Int Immunopharmacol 3(3):319-328. (Pubitemid 36293960)
12. Green MR, et al. (2006) Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17(8):1263-1268. (Pubitemid 44288216)
13. Barenholz Y (2012) Doxil® - the first FDA-approved nano-drug: Lessons learned. J Control Release 160(2):117-134.
14. Davis ME (2002) Non-viral gene delivery systems. Curr Opin Biotechnol 13(2):128-131.
15. Ogris M, Wagner E (2002) Targeting tumors with non-viral gene delivery systems. Drug Discov Today 7(8):479-485. (Pubitemid 34532575)
16. Pack DW, Hoffman AS, Pun S, Stayton PS (2005) Design and development of polymers for gene delivery. Nat Rev Drug Discov 4(7):581-593. (Pubitemid 40975711)
17. Park TG, Jeong JH, Kim SW (2006) Current status of polymeric gene delivery systems. Adv Drug Deliv Rev 58(4):467-486. (Pubitemid 43949425)
18. Boussif O, et al. (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci USA 92(16):7297-7301.
19. Oh YK, et al. (2001) Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes. Gene Ther 8(20):1587-1592.
20. Lavergne E, et al. (2003) Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res 63(21):7468-7474. (Pubitemid 37413490)
21. Lavergne E, et al. (2004) Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 173(6):3755-3762. (Pubitemid 39280737)
22. Hua H, et al. (2007) Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene Ther 14(9):815-818. (Pubitemid 47262754)
23. Jeudy G, et al. (2008) Polyethylenimine-mediated in vivo gene transfer of a transmembrane superantigen fusion construct inhibits B16 murine melanoma growth. Cancer Gene Ther 15(11):742-749.
24. Kang Y, et al. (2009) Tumor-directed gene therapy in mice using a composite nonviral gene delivery system consisting of the piggyBac transposon and polyethylenimine. BMC Cancer 9(1):126.
25. Amit D, Hochberg A (2010) Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. J Transl Med 8(1):134.
26. Hine CM, Seluanov A, Gorbunova V (2012) Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer. Mol Ther 20(2):347-355.
27. Caldas H, Jaynes FO, Boyer MW, Hammond S, Altura RA (2006) Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy. Mol Cancer Ther 5(3):693-703.
28. Chumakova OV, et al. (2008) Composition of PLGA and PEI/DNA nanoparticles improves ultrasound-mediated gene delivery in solid tumors in vivo. Cancer Lett 261(2):215-225.
29. Bhang HE, Gabrielson KL, Laterra J, Fisher PB, Pomper MG (2011) Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat Med 17(1):123-129.
30. Taljaard M, et al. (2010) Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): The first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. Am Heart J 159(3):354-360.
31. Lisziewicz J, et al. (2012) Single DermaVir immunization: Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1-infected individuals. PLoS ONE 7(5):e35416.
32. Sidi AA, et al. (2008) Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 overexpressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol 180(6):2379-2383.
33. Ericson K, et al. (2010) Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci USA 107(6):2598-2603.
34. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2(3):214-221.
35. Goula D, et al. (1998) Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther 5(9):1291-1295. (Pubitemid 28448439)
36. Boeckle S, et al. (2004) Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J Gene Med 6(10):1102-1111. (Pubitemid 40228122)
37. Zhou J, et al. (2012) Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nat Mater 11(1):82-90.
38. Ashley CE, et al. (2011) The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 10(5):389-397.
39. Filipe V, Hawe A, JiskootW(2010) Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27(5):796-810.
40. Bhise NS, Shmueli RB, Gonzalez J, Green JJ (2012) A novel assay for quantifying the number of plasmids encapsulated by polymer nanoparticles. Small 8(3):367-373.
41. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC (2009) Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9(5):1909-1915.